Last reviewed · How we verify
ARI-ORAL
ARI-ORAL is a Small molecule drug developed by University of California, Los Angeles. It is currently FDA-approved. Also known as: aripiprazole, Abilify.
ARI-ORAL is a vaccine component that induces an immune response, and it has been studied in clinical trials for various conditions including Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma, Orthodontic Pain, and Orthodontic Patient Experience. ARI-ORAL has been investigated in combination with apalutamide and cetrelimab in a clinical trial for treatment-emergent Small Cell Neuroendocrine Prostate Cancer.
At a glance
| Generic name | ARI-ORAL |
|---|---|
| Also known as | aripiprazole, Abilify |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (PHASE1,PHASE2)
- Comparison of Different Debonding Techniques of Clear Aligner Attachments (NA)
- Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG (PHASE3)
- Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer (PHASE2)
- VA Aripiprazole vs Esketamine for Treatment Resistant Depression (PHASE4)
- Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (PHASE4)
- Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (PHASE1)
- Quantitative Measurement of ARI (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARI-ORAL CI brief — competitive landscape report
- ARI-ORAL updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI
Frequently asked questions about ARI-ORAL
What is ARI-ORAL?
Who makes ARI-ORAL?
Is ARI-ORAL also known as anything else?
What development phase is ARI-ORAL in?
Related
- Manufacturer: University of California, Los Angeles — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: aripiprazole, Abilify
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing